Myovant Sciences to Host Webcast and Conference Call at 8:30 am E.T. Wed\, Apr 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study